EpoRepair: Erythropoietin for the Repair of Cerebral Injury in Very Preterm Infants
Study Details
Study Description
Brief Summary
The purpose of this randomized and placebo-controlled EpoRepair trial is to evaluate the effect of intravenously administered recombinant human erythropoietin (Epo) as compared to placebo in preterm infants with brain damage on neurological development until five years od age.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Detailed Description
Worldwide, 1% of all infants are born very preterm with less than 32 weeks of gestation, which is more than 2 months before expected date of delivery. If these smallest infants suffer in addition to prematurity a second hit, such as intraventricular hemorrhage or parenchymal infarction, they are at high risk for learning disabilities, mental retardation, and cerebral palsy in later life.
Intraventricular hemorrhage and parenchymal infarction occur in about 12% of very preterm infants, mostly in the very smallest and within the first few days after birth, and can be recorded by cranial ultrasound. Except for shunt insertion to divert cerebrospinal fluid in infants with posthemorrhagic hydrocephalus and possibly the removal of blood clots, there is no treatment for established intracerebral bleeding, and no medical therapies exist to ameliorate the neurodevelopmental sequelae.
Apart from stimulating production of red blood cells in the bone marrow, recombinant human erythropoietin (Epo) has been shown to exert neuroprotective action in a variety of animal models and in clinical studies. Epo administration has been found to be beneficial and safe in randomized controlled trials (RCT) involving adult and infant patients.
Observational data suggest that Epo administered to very preterm infants in order to prevent from anemia improves long-term cognitive outcomes until school-age especially in those infants who had suffered intracerebral bleeding. These data, however, are observational and therefore do not allow for any firm conclusions or recommendations. The hypothesis generated by these data calls for confirmation or refutation by an RCT designed to address this question.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: recombinant human Erythropoietin (Epo) Epo 2000 U in normal saline per ml/kg of body weight 5 times intravenously, total dosage 10000 U per 5ml/kg. In detail: For loading 3 times beginning at day 5 of life (± 2 days), followed at 24 hours and 48 hours later. For maintenance 2 times, at day 10 and day 17 after the first study medication. |
Drug: recombinant human Erythropoietin
i.v. administration
Other Names:
|
| Placebo Comparator: Control Placebo 1 ml normal saline/kg of body weight 5 times intravenously, total dosage 5 ml/kg. In detail: For loading 3 times beginning at day 5 of life (± 2 days), followed at 24 hours and 48 hours later. For maintenance 2 times, at day 10 and day 17 after the first study medication. |
Drug: Placebo
i.v. administration
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Neurodevelopmental outcome [5 years]
With 5 years of age, composite intelligence quotient to be assessed by standardized IQ tests.
Secondary Outcome Measures
- Biomarker cranial MRI [40 weeks postmenstrual age]
Brain injury score assessed on cranial MRI, including brain maturation score and white matter and gray matter injury scores, as biomarker for long-term neurodevelopmental outcome.
- Safety [Infants will be followed for the duration of hospital stay, an expected average of 14 weeks]
Analysis will be performed to get insight about the distributions of adverse events and other safety relevant outcomes between groups.
- Neurodevelopmental outcome [2 years]
Bayley Scales of Infant Development (BSID-III) and the presence or absence of impairment of motor function (cerebral palsy) and neurosensory function (blindness or deafness) will be assessed with 18 to 24 months.
- Biomarker serial cranial ultrasound [Infants will be followed for the duration of hospital stay, an expected average of 14 weeks]
Cranial ultrasound is a useful point of care method to detect, confirm and monitor brain damage including intracerebral bleeding. It is part of clinical routine for the duration of hospital stay.
- Overall developmental outcome [5 years]
Neurological and formal psychological examination. Normal Overall developmental outcome is classified as normal if IQ >84 and without one or more of the following: motor impairment, cognitive impairment, behavior problems, poor general health, severe hearing loss, or bilateral blindness.
Other Outcome Measures
- Course of intracerebral bleeding [Infants will be followed for the duration of hospital stay, an expected average of 14 weeks]
Course of intracerebral bleeding from onset until term equivalent age with additional visits at 28 days of life and 36 weeks postmenstrual age. No remaining lesions as recorded by cranial ultrasound Persisting posthemorrhagic hydrocephalus without any drainage Persisting posthemorrhagic hydrocephalus with repetitive but transient csf-drainage Posthemorrhagic hydrocephalus with permanent csf-drainage Convulsions and other abnormalities or medications related to intracerebral bleeding
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Infants with less than 32 weeks of gestation and/or less than 1500 g weight at birth
-
Intraventricular hemorrhage and/or hemorrhagic parenchymal infarction
-
Less than 8 days of life
-
Informed written parental consent
Exclusion Criteria:
-
Genetically defined syndrome
-
Severe congenital malformation adversely affecting life expectancy and/or neurodevelopment
-
A priory palliative care
-
Unlikely to participate at 5-year follow-up examination
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Medical University of Vienna | Vienna | Austria | ||
| 2 | Kantonsspital Aarau | Aarau | Switzerland | 5001 | |
| 3 | University Children's Hospital Basel (UKBB) | Basel | Switzerland | 4031 | |
| 4 | University Hospital Bern | Bern | Switzerland | 3010 | |
| 5 | Kantonsspital Graubünden | Chur | Switzerland | 7000 | |
| 6 | Centre Hospitalier Universitaire Vaudois (CHUV) | Lausanne | Switzerland | 1011 | |
| 7 | Ostschweizer Kinderspital | St. Gallen | Switzerland | 9006 | |
| 8 | University Hospital Zurich | Zurich | Switzerland | 8091 |
Sponsors and Collaborators
- University of Zurich
- Swiss National Science Foundation
Investigators
- Principal Investigator: Sven Wellmann, MD, University of Zurich
- Study Chair: Hans Ulrich Bucher, MD, PhD, University of Zurich
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
- EpoRepair
- 2013DR3204